CASE REPORT article
Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1545896
Extra-Skeletal Ewing Sarcoma in a 63-Year-Old Female with a History of Triple-Negative Breast Cancer: A case Report and Literature Review
Provisionally accepted
- 1Department of Internal Medicine, Loma Linda University Medical Center – Murrieta, Murrieta, United States
- 2Division of Medical Oncology and Hematology, Department of Internal Medicine, Loma Linda University, Loma Linda, California, United States
- 3Division of Medical Oncology and Hematology, Department of Internal Medicine, Loma Linda University Medical Center – Murrieta, Murrieta, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Ewing sarcoma (ES), particularly Extra-skeletal Ewing sarcoma (EES), is a rare, aggressive tumor predominantly affecting adolescents and young adults, yet it can occur in older patients, leading to misdiagnosis and delay in treatment. The standard approach includes surgical resection, chemotherapy, and radiation therapy for unresectable disease. This case report presents a 63-year-old female patient with a history of triple-negative breast cancer, who was discovered to have a soft tissue tumor in the left medial thigh. Initially misdiagnosed as rhabdomyosarcoma, the diagnosis of EES was ultimately confirmed via RNA sequencing revealing the EWSR1-FLI1 fusion gene. She underwent neoadjuvant chemotherapy followed by radical resection of the tumor.
Keywords: Extra-skeletal Ewing sarcoma, EWSR1-FLI1 fusion, EWSR1-ERG fusion, surgical resection, chemotherapy, radiation therapy
Received: 16 Dec 2024; Accepted: 21 Apr 2025.
Copyright: © 2025 HO, Safavi, Jeon and Mendoza. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Evelyn Mendoza, Division of Medical Oncology and Hematology, Department of Internal Medicine, Loma Linda University Medical Center – Murrieta, Murrieta, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.